J Biol Regul Homeost Agents. 2011 Apr-Jun;25(2):295-7.
Th9 is a new T cell subset characterized by IL-9 production. It has been reported that serum IL-9 levels are related with symptom severity in patients with allergic rhinitis (AR). This study is aimed at investigating whether serum IL-9 may be modulated by sublingual immunotherapy (SLIT) in patients with persistent AR due to Parietaria allergy. Twenty-one AR patients (9 males, median age 41 years) successfully treated with SLIT and 52 AR patients (25 males, median age 34 years) treated only with drugs were evaluated during the pollen season. Serum IL-9 was dosed in all patients. SLIT-treated patients showed significantly lower serum IL-9 levels than untreated AR patients (p <0.0001). In conclusion, this preliminary study shows that a single pre-seasonal SLIT course might modulate serum IL-9.
Th9 是一种新的 T 细胞亚群，其特征是能够产生白细胞介素 9（IL-9）。据报道，血清 IL-9 水平与变应性鼻炎（AR）患者的症状严重程度有关。本研究旨在探讨舌下免疫疗法（SLIT）是否可调节花粉季节中对豚草过敏的持续性 AR 患者的血清 IL-9。21 名接受 SLIT 治疗的 AR 患者（9 名男性，中位年龄 41 岁）和 52 名仅接受药物治疗的 AR 患者（25 名男性，中位年龄 34 岁）在花粉季节进行了评估。所有患者均测定了血清 IL-9。与未接受治疗的 AR 患者相比，接受 SLIT 治疗的患者的血清 IL-9 水平显著降低（p<0.0001）。总之，这项初步研究表明，一个单一的季节性 SLIT 疗程可能会调节血清 IL-9。
